This systematic review and network meta-analysis evaluates the evidence to guide clinical decision-making for locally advanced or inoperable HR+/HER2- breast cancer.<h4>Methods</h4>We analyzed phase II/III neoadjuvant clinical trials in HR+/HER2- breast cancer. Here, ERBB2 is linked to breast cancer.